The Cellular Therapy Form was originally designed to collect data on stem cells, progenitors or mature cells, such as T-lymphocytes, unmanipulated, as well as any other cell type undergoing biological or biotechnological manipulation. It has been revised with the primary focus on collecting data on CAR-T cells, used for treatment in combination with HSCT or alone, and including advanced therapeutic medicinal products (ATMP), as well as data on the clinical characteristics and outcomes of the patients. It has been employed to support the EBMT registry.

**Educational events in 2023**
- Joint CMWP-CTIWP educational meeting
- 5th EBMT/EHA European CAR T-Cell hybrid Meeting

**CTIWP at 50th Annual Meeting of EBMT**
**Monday, April 15th**
**Cell Therapy Day**
- 09:00-17:45 LOMOND

**Tuesday, April 16th**
**Scientific Business Meeting (on-site)**
- 12:45 – 14:00 Room: FORTH

**Oral presentations**
1. Esteban Arrieta Bolaños – HLA mismatching and survival after HCT in the PTCY era: a comprehensive study by the EBMT CTIWP;
2. Antoine Capes - PTCY Plus ATG Compared To PTCY Alone In Hapoidentical Transplantation With Pbscs: A Retrospective Study On Behalf Of The CTIWP Of The EBMT;

**Poster presentations**
1. Paolo Pedrazzoli – High-dose chemotherapy with stem cell transplantation in adult primary mediastinal germ cell tumors. A retrospective study of the EBMT, CTIWP;
2. Florent Malard - Choice of commercially available CAR T-cells for aggressive lymphoma: a survey of behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT;

**CURRENT STUDIES**
- Associations between HLA Evolutionary Divergence and clinical outcome of matched related or unrelated stem cell transplantation (P. Crivello)
- Current use of donor lymphocyte infusions after allogenic stem cell transplantation: a survey on behalf of the CTIWP of the EBMT (N. Santoro)
- Frequency of CAR-T cell manufacturing failures and Out-of-Specification products in the real-world setting (N. Worel)
- Defining protective T-cell thresholds following allogeneic HSCT (M. Cavazzana)
- MSCs for treatment of steroid-resistant acute GvHD (L. van Hussen-Daenen)
- State-of-the-art of immune monitoring procedures after chimeric antigen receptor T-cell therapies in EBMT centers (S. Pagliuca)
- PTCY Plus ATG Compared To PTCY Alone In Hapoidentical Transplantation With Pbscs: A Retrospective Study On Behalf Of The CTIWP Of The EBMT (A. Capes)

**KEY PUBLICATIONS 2023**
- Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT
G Battipaglia et al., Bone Marrow Transplantation, 2023 Dec;58(12):1419-1421

- Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party
R. Greco et al., Bone Marrow Transplantation, 2023 May;58(5):603-606

- Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party
M. De Witte et al., Bone Marrow Transplantation. 2023 Jun;58(6):719-722

- Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey
P. Comoli et al., Annals of Oncology, 2023 Dec;S0923-7534(23)05116-5

**UPCOMING EVENTS**
- Monday, April 15
  - High-dose chemotherapy with stem cell transplantation in adult primary mediastinal germ cell tumors. A retrospective study of the EBMT, CTIWP;
- Tuesday, April 16
  - Choice of commercially available CAR T-cells for aggressive lymphoma: a survey of behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT;

**CONTACT CTIWP**
Would you like to receive information on our studies, submit a study protocol, or become a CTIWP member and help advance our research? Feel free to contact us at: ctwpebmt@lumc.nl